Recommendation of the President – XMTVI Maxamum

On 4 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 138/2024 on the appropriateness of issuing approvals for reimbursement of the foodstuff for special nutritional use: XMTVI Maxamum for the indication: methylmalonic/propionic aciduria in pediatric patients aged 8 years and older and adults, including pregnant women, and XMTVI Maxamaid for the indication: methylmalonic/propionic aciduria in infants and young children

Publication in Public Information Bulletin (BIP) >>